Protective efficacy in mice of monovalent and trivalent live attenuated influenza vaccines in the background of cold-adapted A/X-31 and B/Lee/40 donor strains
- PMID: 24342248
- DOI: 10.1016/j.vaccine.2013.12.002
Protective efficacy in mice of monovalent and trivalent live attenuated influenza vaccines in the background of cold-adapted A/X-31 and B/Lee/40 donor strains
Abstract
Influenza virus continues to take a heavy toll on human health and vaccination remains the mainstay of efforts to reduce the clinical impact imposed by viral infections. Proven successful for establishing live attenuated vaccine donor strains, cold-adapted live attenuated influenza vaccines (CAIVs) have become an attractive modality for controlling the virus infection. Previously, we developed the cold-adapted strains A/X-31 and B/Lee/40 as novel donor strains of CAIVs against influenza A and B viruses. In this study, we investigated the protective immune responses of both mono- and trivalent vaccine formulations in the mouse model. Two type A vaccines and one type B vaccine against A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Shangdong/7/97 in the background of the A/X-31 ca or B/Lee/40 ca were generated by a reassortment procedure and evaluated for their immunogenicity and protective efficacy. Each monovalent vaccine elicited high levels of serum antibodies and conferred complete protection against homologous wild type virus infection. As compared to the monovalent vaccines, trivalent formulation induced higher levels of type A-specific serum antibodies and slightly lower levels of type B-specific antibodies, suggesting an immunological synergism within type A viruses and an interference in the replication of type B virus. Relatively lower type B-specific immunogenicity in trivalent vaccine formulation could be effectively implemented by increasing the vaccine dose of influenza B virus. These results of immunogenicity, protection efficacy, and immunological synergism between type A vaccines provide an experimental basis for optimal composition of trivalent vaccines for subsequent developments of multivalent CAIVs against seasonal and pandemic influenza viruses.
Keywords: A/X-31 ca; B/Lee/40 ca; Influenza virus; Mouse study; Seasonal influenza vaccine; Trivalent vaccine.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Development and characterization of a live attenuated influenza B virus vaccine candidate.Vaccine. 2008 Feb 13;26(7):874-81. doi: 10.1016/j.vaccine.2007.12.022. Epub 2008 Jan 7. Vaccine. 2008. PMID: 18207290
-
Immunogenicity and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1 influenza vaccines.Vaccine. 2013 Jul 18;31(33):3339-46. doi: 10.1016/j.vaccine.2013.05.080. Epub 2013 Jun 3. Vaccine. 2013. PMID: 23742997
-
Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.Vaccine. 2006 Mar 10;24(11):1966-74. doi: 10.1016/j.vaccine.2005.10.051. Epub 2005 Nov 8. Vaccine. 2006. PMID: 16343703
-
Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference.Expert Rev Vaccines. 2011 Aug;10(8):1131-41. doi: 10.1586/erv.11.73. Expert Rev Vaccines. 2011. PMID: 21854309 Review.
-
Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.Drugs R D. 2003;4(5):312-9. doi: 10.2165/00126839-200304050-00007. Drugs R D. 2003. PMID: 12952502 Review.
Cited by
-
Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity.Vaccines (Basel). 2020 Nov 16;8(4):683. doi: 10.3390/vaccines8040683. Vaccines (Basel). 2020. PMID: 33207559 Free PMC article.
-
Immunodominance hierarchy of influenza subtype-specific neutralizing antibody response as a hurdle to effectiveness of polyvalent vaccine.Hum Vaccin Immunother. 2018;14(10):2537-2539. doi: 10.1080/21645515.2018.1482172. Epub 2018 Jun 28. Hum Vaccin Immunother. 2018. PMID: 29852081 Free PMC article.
-
Computationally Optimized Hemagglutinin Proteins Adjuvanted with Infectimune® Generate Broadly Protective Antibody Responses in Mice and Ferrets.Vaccines (Basel). 2024 Dec 2;12(12):1364. doi: 10.3390/vaccines12121364. Vaccines (Basel). 2024. PMID: 39772026 Free PMC article.
-
A Computationally Optimized Broadly Reactive Hemagglutinin and Neuraminidase Vaccine Boosts Antibody-Secreting Cells and Induces a Robust Serological Response, Preventing Lung Damage in a Pre-Immune Model.Vaccines (Basel). 2024 Jun 24;12(7):706. doi: 10.3390/vaccines12070706. Vaccines (Basel). 2024. PMID: 39066344 Free PMC article.
-
Safety, Immunogenicity, and Protective Efficacy of an H5N1 Chimeric Cold-Adapted Attenuated Virus Vaccine in a Mouse Model.Viruses. 2021 Dec 3;13(12):2420. doi: 10.3390/v13122420. Viruses. 2021. PMID: 34960689 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials